| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 29, 2021 4:01 P.M. |
| Form: | S-1 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | September 29, 2021 4:01 P.M. |
| Form: | S-1 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
3 - Tango Therapeutics, Inc. (0001819133) (Issuer)
4 - Tango Therapeutics, Inc. (0001819133) (Issuer)
– Business combination transaction with BCTG Acquisition Corp., a special purpose acquisition company sponsored by Boxer Capital, completed today – – Combined company Tango Therapeutics, Inc. will be listed on the Nasdaq Capital Market under ticker symbol "TNGX" – – Total expected cash position of approximately $515 million including gross proceeds from transaction totaling approximately $342 million, combining funds held in BCTG's trust account and PIPE financing once completed – CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. ("Tango Therapeutics" or "Tango"), a biotechnology company committed to discovering and delivering the next generation of prec
- Leading institutional investors commit $186 million through a common stock private investment in public equity ("PIPE") led by Boxer Capital - Total proceeds expected to be approximately $353 million, combining funds held in trust by BCTG Acquisition Corp and the PIPE financing - Merger expected to be completed in third quarter of 2021, and Combined Company will be listed on Nasdaq under the ticker "TNGX" – - Joint investor conference call to discuss the proposed transaction today, Wednesday, April 14, at 10:00 a.m. ET – Tango Therapeutics, a biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, and BCTG Acquisition Corp. (NA
S-8 - Tango Therapeutics, Inc. (0001819133) (Filer)
424B3 - Tango Therapeutics, Inc. (0001819133) (Filer)
EFFECT - Tango Therapeutics, Inc. (0001819133) (Filer)
SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13D - Tango Therapeutics, Inc. (0001819133) (Subject)
SC 13G - Tango Therapeutics, Inc. (0001819133) (Subject)